Cryoport, Inc. (NASDAQ:CYRX - Get Free Report)'s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $7.82 and traded as high as $8.61. Cryoport shares last traded at $8.51, with a volume of 291,213 shares changing hands.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on CYRX shares. UBS Group raised their target price on Cryoport from $7.00 to $9.00 and gave the company a "neutral" rating in a research report on Friday, October 18th. Roth Mkm dropped their target price on shares of Cryoport from $18.00 to $15.00 and set a "buy" rating for the company in a report on Friday, November 8th. Finally, Guggenheim initiated coverage on shares of Cryoport in a research report on Thursday, December 19th. They issued a "buy" rating and a $11.00 target price for the company. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $12.29.
Read Our Latest Research Report on CYRX
Cryoport Stock Down 3.5 %
The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The business has a 50 day simple moving average of $7.71 and a 200-day simple moving average of $7.83. The firm has a market capitalization of $420.66 million, a price-to-earnings ratio of -2.52 and a beta of 1.58.
Insider Activity at Cryoport
In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of the firm's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the completion of the sale, the director now owns 59,497 shares of the company's stock, valued at $443,847.62. This trade represents a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jerrell Shelton sold 50,000 shares of the company's stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $6.51, for a total value of $325,500.00. Following the completion of the transaction, the chief executive officer now directly owns 731,897 shares in the company, valued at approximately $4,764,649.47. This trade represents a 6.39 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 109,869 shares of company stock valued at $735,673. 10.10% of the stock is owned by company insiders.
Institutional Investors Weigh In On Cryoport
Institutional investors have recently made changes to their positions in the stock. Fred Alger Management LLC lifted its stake in Cryoport by 49.9% during the 3rd quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company's stock worth $21,887,000 after acquiring an additional 898,481 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Cryoport by 2.6% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,035,586 shares of the company's stock worth $14,066,000 after purchasing an additional 52,103 shares during the period. Thematics Asset Management lifted its position in shares of Cryoport by 176.2% during the third quarter. Thematics Asset Management now owns 1,705,000 shares of the company's stock worth $13,828,000 after purchasing an additional 1,087,800 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Cryoport by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,097,369 shares of the company's stock valued at $8,902,000 after purchasing an additional 38,520 shares during the period. Finally, State Street Corp grew its holdings in shares of Cryoport by 2.8% in the third quarter. State Street Corp now owns 1,003,080 shares of the company's stock valued at $8,135,000 after purchasing an additional 27,438 shares in the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.
About Cryoport
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Further Reading
Before you consider Cryoport, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.
While Cryoport currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
